NCT05166668View on ClinicalTrials.gov

Letrozole /GnRH Antagonist Protocol in Women Over 40 Years Undergoing ICSI Cycle

NACompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

February 10, 2025

Study Completion Date

February 10, 2025

Conditions

Ovarian Stimulation

Interventions

DRUG

Letrozole 2.5mg tablet

letrozole (femara, Novartis) orally in a dose of 2.5 mg daily, on day 2 of cycle for 5 days and gonadotropins (300-450 IU) IM start on cycle day 3. then the dose modulated according to response

Trial Locations (1)

11111

Menoufia University hospital, Shibīn al Kawm

All Listed Sponsors

lead

Menoufia University

OTHER

NCT05166668 - Letrozole /GnRH Antagonist Protocol in Women Over 40 Years Undergoing ICSI Cycle | Biotech Hunter | Biotech Hunter